The Catalyst In Review: Week of December 3

The Catalyst In Review: Week of December 3

12.07.12 | By

This week we featured a number of posts on Medicare Part D, research and development and innovation.

Today marks the end of the 2013 Part D open enrollment period, and the National Grange, the National Alliance of State Pharmacy Associations and the Healthcare Leadership Council all weighed in with their perspectives on the benefits of Part D and how to help seniors and persons with disabilities get the most out of the program. Additionally, they highlighted the importance of taking ownership of one's health alongside having a Part D plan in place.

The importance of research, development and innovation was also a focus as a recent report from the President's Council of Advisors on Science and Technology reinforced the need for the U.S. to remain the world leader in innovation. Similarly, PhRMA's Vice President of International Affairs and Advocacy Jay Taylor authored a post about the Trans-Pacific Partnership agreement and how strong intellectual property protections in the agreement are essential to help foster innovation and economic growth.

On December 5th, we took a moment to highlight a Forbes article responding to an article in The Washington Post on clinical trials. The piece noted that the biopharmaceutical industry has made great progress on the issue of clinical trial transparency and discussed how related data should be disseminated in a way that is scientifically robust. At the same time, maintaining protection for individual privacy and incentives for future innovation is critical.

This is just a sampling of some of the most interesting content posted on the blog this week. Stay tuned, weigh in with your comments and check back often as we continue to keep you apprised of the information and issues that impact the industry.

More On PhRMA — powered by PhRMApedia


Cost in Context